All manuscripts
Publications CAR T Cells

Proof of concept of a fully enclosed CAR-T process without use of a biosafety cabinet

Published Journal Cell and Gene Therapy Insights

Share
11 pages Proof of concept of a fully enclosed CAR-T process without use of a biosafety cabinet — Cell and Gene Therapy Insights, 2025

Overview

This study evaluates a fully enclosed CAR-T manufacturing process eliminating biosafety cabinets. It uses CellSeal Connect vials for cryopreservation and G-Rex® for cell activation and expansion. Results show comparable cell expansion, viability, and transduction to standard open processes.

What this paper found

CellSeal Connect closed vials performed comparably to standard cryovials for storing starting T cells and lentiviral vector in a CAR-T process, supporting manufacture without a biosafety cabinet. Enriched CD4/CD8 T cells from three healthy donors were cryopreserved in either container, thawed, activated, transduced with an anti-CD19 CAR/GFP lentiviral vector at an MOI of 1.9 and expanded for seven days. Fold expansion was 38.8, 34.6 and 37.8 with CellSeal Connect versus 33.4, 39.9 and 34.5 with cryovials, and transduction was 43 to 54% versus 46 to 59%. Viability stayed high at all time points in all donors. Final product frozen in CellSeal CryoCases had post-thaw viability of 94.8 to 96.9%, versus 97.1 to 97.5% in cryovials.

Note: Proof-of-concept study using cells from three healthy donors.

This study demonstrates that CAR-T manufacturing can be fully enclosed when appropriate containers are used for both starting cells and viral vectors. — Jon Pileggi, Menna Siddiqui, Carlos Ramos, Diana Santana, Christopher Alvarado, Brittany Miller, Cathy Wang, Forrest Kan, Chantale Bernatchez, Cell and Gene Therapy Insights

Study details

Authors
Jon Pileggi, Menna Siddiqui, Carlos Ramos, Diana Santana, Christopher Alvarado, Brittany Miller, Cathy Wang, Forrest Kan, Chantale Bernatchez
Institution
Cell Therapy Manufacturing Center (CTMC), Houston, TX, USA
Journal
Cell and Gene Therapy Insights
Year
2025
Cell type(s)
CAR T Cells
Application area
Hematologic malignancy
Study phase
Preclinical

How G-Rex® was used

After thawing, washing and resuspension in culture medium, T cells from three healthy donors were activated with ImmunoCult CD3/CD28/CD2 T Cell activator in G-Rex® flasks. The next day cultures were transduced with an anti-CD19 CAR/GFP lentiviral vector at an MOI of 1.9, incubated for 48 hours, then fed with complete media and incubated for a further 96 hours. Fold expansion from seed to day 7 ranged from 33.4× to 39.9× across donors and starting-cell containers.

Explore related

Full citation

Pileggi J, Siddiqui M, Ramos C, et al. Proof of concept of a fully enclosed CAR-T process without use of a biosafety cabinet. Cell and Gene Therapy Insights. 2025;11(7):897–907.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →